Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Scientific Enters Bridge Credit Agreement for up to €9.25 Billion

NEW YORK – Thermo Fisher Scientific said on Thursday that on April 17, it entered into a bridge credit agreement with JPMorgan Chase and Morgan Stanley Senior Funding for up to €9.25 billion ($9.96 billion).

The company had announced on March 3 that the lenders had committed to the debt financing in connection with its proposed acquisition of Qiagen.

Under the terms of the agreement, Thermo Fisher is obtaining a 364-day senior unsecured bridge loan facility in the principal amount of up to €9.25 billion. Loans under the agreement will be available to fund the purchase of equity securities of Qiagen and to pay all or a portion of the cost incurred in connection with this.

Thermo Fisher can draw on the funds on the closing date of the acquisition and again within 120 days after the closing date.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.